Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized azithromycin + metronidazole added to standard induction therapy in pediatric Crohn's disease
NL-OMON55227Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azithromycin and metronidazole in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Sustained remission by 12 months. Started Aug 2021; status: active, not recruiting.
02
Drugs
azithromycinmetronidazole
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON55227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55227.